The closing price of Marinus Pharmaceuticals Inc (NASDAQ: MRNS) was $8.48 for the day, down -4.18% from the previous closing price of $8.85. In other words, the price has decreased by -$0.37 from its previous closing price. On the day, 532900 shares were traded.
Ratios:
Our analysis of MRNS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.01 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 6.58 whereas as Long-Term Debt/Eq ratio is at 5.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Oppenheimer on August 11, 2023, Downgraded its rating to Perform and sets its target price to $9 from $14 previously.
On January 20, 2023, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $23.
On September 30, 2020, Truist started tracking the stock assigning a Buy rating and target price of $35.Truist initiated its Buy rating on September 30, 2020, with a $35 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 20 ’24 when Shafer Christina sold 2,153 shares for $9.56 per share. The transaction valued at 20,583 led to the insider holds 60,308 shares of the business.
MANNING MARTHA E sold 1,894 shares of MRNS for $18,126 on Feb 20 ’24. The SVP, GEN. COUNSEL & CORP. SEC. now owns 52,966 shares after completing the transaction at $9.57 per share. On Feb 16 ’24, another insider, Braunstein Scott, who serves as the CHAIRMAN AND CEO of the company, sold 11,850 shares for $9.94 each. As a result, the insider received 117,789 and left with 223,512 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNS now has a Market Capitalization of 483.86M and an Enterprise Value of 407.32M. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.95 while its Price-to-Book (P/B) ratio in mrq is 27.61. Its current Enterprise Value per Revenue stands at 13.14 whereas that against EBITDA is -3.25.
Stock Price History:
Over the past 52 weeks, MRNS has reached a high of $11.26, while it has fallen to a 52-week low of $5.57. The 50-Day Moving Average of the stock is 9.99, while the 200-Day Moving Average is calculated to be 8.54.
Shares Statistics:
MRNS traded an average of 436.30K shares per day over the past three months and 575.86k shares per day over the past ten days. A total of 54.58M shares are outstanding, with a floating share count of 50.86M. Insiders hold about 6.92% of the company’s shares, while institutions hold 94.02% stake in the company. Shares short for MRNS as of Feb 15, 2024 were 3.57M with a Short Ratio of 8.18, compared to 3.85M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.54% and a Short% of Float of 6.59%.
Earnings Estimates
The firm’s stock currently is rated by 10 analysts. On average, analysts expect EPS of -$0.63 for the current quarter, with a high estimate of -$0.5 and a low estimate of -$0.69, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$0.58, with high estimates of -$0.52 and low estimates of -$0.66.
Analysts are recommending an EPS of between -$2.06 and -$2.98 for the fiscal current year, implying an average EPS of -$2.37. EPS for the following year is -$1.88, with 11 analysts recommending between -$1.29 and -$2.6.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 11 analysts. It ranges from a high estimate of $15.02M to a low estimate of $6.25M. As of the current estimate, Marinus Pharmaceuticals Inc’s year-ago sales were $10.38M, an estimated decrease of -12.40% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $9.25M, an increase of 52.10% over than the figure of -$12.40% in the same quarter last year. There is a high estimate of $11.8M for the next quarter, whereas the lowest estimate is $6.1M.
A total of 11 analysts have provided revenue estimates for MRNS’s current fiscal year. The highest revenue estimate was $54.3M, while the lowest revenue estimate was $33.22M, resulting in an average revenue estimate of $40.53M. In the same quarter a year ago, actual revenue was $30.99M, up 30.80% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $68.81M in the next fiscal year. The high estimate is $127.7M and the low estimate is $42.5M. The average revenue growth estimate for next year is up 69.80% from the average revenue estimate for this year.
